Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Osteoporosis

  Free Subscription


Articles published in J Clin Endocrinol Metab

Retrieve available abstracts of 101 articles:
HTML format
Text format



Single Articles


    July 2018
  1. HAMILTON EJ, Drinkwater JJ, Chubb SAP, Rakic V, et al
    A ten-year prospective study of bone mineral density and bone turnover in males and females with type 1 diabetes.
    J Clin Endocrinol Metab. 2018 Jul 18. pii: 5055538. doi: 10.1210/jc.2018-00850.
    PubMed     Text format     Abstract available


  2. LIN SM, Wang JH, Liang CC, Huang HK, et al
    Statin use is associated with decreased osteoporosis and fracture risks in stroke patients.
    J Clin Endocrinol Metab. 2018 Jul 2. pii: 5047290. doi: 10.1210/jc.2018-00652.
    PubMed     Text format     Abstract available


  3. SHEN J, Griffith JF, Zhu TY, Tang P, et al
    Bone Mass, Microstucture And Strength Can Discriminate Vertebral Fracture In Patients on Long-Term Steroid Treatment.
    J Clin Endocrinol Metab. 2018 Jul 2. pii: 5047293. doi: 10.1210/jc.2018-00490.
    PubMed     Text format     Abstract available


    June 2018
  4. KIM K, Kim IJ, Pak K, Kim SJ, et al
    Evaluation of bone mineral density using DXA and central QCT in postmenopausal patients under thyrotropin suppressive therapy.
    J Clin Endocrinol Metab. 2018 Jun 21. pii: 5041930. doi: 10.1210/jc.2017-02704.
    PubMed     Text format     Abstract available


  5. LEWIECKI EM, Blicharski T, Goemaere S, Lippuner K, et al
    A Phase 3 Randomized Placebo-controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis.
    J Clin Endocrinol Metab. 2018 Jun 20. pii: 5040365. doi: 10.1210/jc.2017-02163.
    PubMed     Text format     Abstract available


    May 2018
  6. KIM SY, Kong IG, Lim H, Choi HG, et al
    Increased risk of sudden sensory neural hearing loss in osteoporosis: A longitudinal follow up study.
    J Clin Endocrinol Metab. 2018 May 28. pii: 5005943. doi: 10.1210/jc.2018-00717.
    PubMed     Text format     Abstract available


  7. BONE HG, Cosman F, Miller PD, Williams GC, et al
    ACTIVExtend: 24 Months of Alendronate after 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.
    J Clin Endocrinol Metab. 2018 May 24. pii: 5001732. doi: 10.1210/jc.2018-00163.
    PubMed     Text format     Abstract available


  8. SUGIYAMA T
    Letter to the Editor: Effects of long-term denosumab on bone histomorphometry and mineralization in women with postmenopausal osteoporosis.
    J Clin Endocrinol Metab. 2018 May 15. pii: 4995803. doi: 10.1210/jc.2018-00886.
    PubMed     Text format    


    April 2018
  9. DEMPSTER DW, Brown JP, Fahrleitner-Pammer A, Kendler D, et al
    Effects of Long-term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis.
    J Clin Endocrinol Metab. 2018 Apr 16. pii: 4970149. doi: 10.1210/jc.2017-02669.
    PubMed     Text format     Abstract available


    March 2018
  10. LIU L, Wen Y, Zhang L, Xu P, et al
    Assessing the associations of blood metabolites with osteoporosis: a Mendelian randomization study.
    J Clin Endocrinol Metab. 2018 Mar 1. pii: 4916908. doi: 10.1210/jc.2017-01719.
    PubMed     Text format     Abstract available


  11. MAKITIE RE, Hackl M, Niinimaki R, Kakko S, et al
    Altered MicroRNA Profile in Osteoporosis Caused by Impaired WNT Signaling.
    J Clin Endocrinol Metab. 2018 Mar 1. pii: 4916912. doi: 10.1210/jc.2017-02585.
    PubMed     Text format     Abstract available


    February 2018
  12. KHOSLA S, Farr JN, Kirkland JL
    Inhibiting Cellular Senescence: A New Therapeutic Paradigm for Age-Related Osteoporosis.
    J Clin Endocrinol Metab. 2018 Feb 7. pii: 4841935. doi: 10.1210/jc.2017-02694.
    PubMed     Text format     Abstract available


  13. KIM BJ, Kwak MK, Ahn SH, Kim H, et al
    Lower Trabecular Bone Score in Patients With Primary Aldosteronism: Human Skeletal Deterioration by Aldosterone Excess.
    J Clin Endocrinol Metab. 2018;103:615-621.
    PubMed     Text format     Abstract available


    January 2018

  14. CORRIGENDUM FOR "Identification of Novel Potentially Pleiotropic Variants Associated With Osteoporosis and Obesity Using the cFDR Method".
    J Clin Endocrinol Metab. 2018 Jan 22. pii: 4819317. doi: 10.1210/jc.2018-00141.
    PubMed     Text format    


  15. GOSSIEL F, Scott JR, Paggiosi MA, Naylor KE, et al
    The effect of teriparatide treatment on circulating periostin and its relationship to regulators of bone formation and BMD in postmenopausal women with osteoporosis.
    J Clin Endocrinol Metab. 2018 Jan 22. pii: 4819314. doi: 10.1210/jc.2017-00283.
    PubMed     Text format     Abstract available


  16. BERGMAN J, Nordstrom A, Nordstrom P
    Alendronate Use and the Risk of Nonvertebral Fracture During Glucocorticoid Therapy: A Retrospective Cohort Study.
    J Clin Endocrinol Metab. 2018;103:306-313.
    PubMed     Text format     Abstract available


    December 2017
  17. SOUCEK O, Schonau E, Lebl J, Willnecker J, et al
    A 6-Year Follow-Up of Fracture Incidence and Volumetric Bone Mineral Density Development in Girls with Turner Syndrome.
    J Clin Endocrinol Metab. 2017 Dec 28. pii: 4780815. doi: 10.1210/jc.2017-02381.
    PubMed     Text format     Abstract available


  18. ANASTASILAKIS AD, Makras P, Pikilidou M, Tournis S, et al
    Changes of circulating micro-RNAs in response to treatment with teriparatide or denosumab in postmenopausal osteoporosis.
    J Clin Endocrinol Metab. 2017 Dec 22. pii: 4772360. doi: 10.1210/jc.2017-02406.
    PubMed     Text format     Abstract available


    November 2017
  19. HU Y, Tan LJ, Chen XD, Liu Z, et al
    Identification of Novel Potentially-pleiotropic Variants Associated With Osteoporosis and Obesity Using cFDR method.
    J Clin Endocrinol Metab. 2017 Nov 14. doi: 10.1210/jc.2017-01531.
    PubMed     Text format     Abstract available


  20. MAZZIOTTI G, Formenti AM, Frara S, Olivetti R, et al
    HIGH PREVALENCE OF RADIOLOGICAL VERTEBRAL FRACTURES IN WOMEN ON TSH-SUPPRESSIVE THERAPY FOR THYROID CARCINOMA.
    J Clin Endocrinol Metab. 2017 Nov 7. doi: 10.1210/jc.2017-01986.
    PubMed     Text format     Abstract available


  21. LEE RH, Sloane R, Pieper C, Lyles KW, et al
    Clinical fractures among older men with diabetes are mediated by diabetic complications.
    J Clin Endocrinol Metab. 2017 Nov 1. doi: 10.1210/jc.2017-01593.
    PubMed     Text format     Abstract available


  22. SINGH-OSPINA N, Maraka S, Rodriguez-Gutierrez R, Davidge-Pitts C, et al
    Effect of Sex Steroids on the Bone Health of Transgender Individuals: A Systematic Review and Meta-Analysis.
    J Clin Endocrinol Metab. 2017;102:3904-3913.
    PubMed     Text format     Abstract available


    September 2017
  23. SAKKA S, Gafni RI, Davies JH, Clarke B, et al
    Bone structural characteristics and response to bisphosphonate treatment in children with Hajdu-Cheney Syndrome.
    J Clin Endocrinol Metab. 2017 Sep 8. doi: 10.1210/jc.2017-01102.
    PubMed     Text format     Abstract available


  24. SMEETS CCJ, van der Steen M, Renes JS, Hokken-Koelega ACS, et al
    Bone Mineral Density After Cessation of GH Treatment in Young Adults Born SGA: A 5-Year Longitudinal Study.
    J Clin Endocrinol Metab. 2017;102:3508-3516.
    PubMed     Text format     Abstract available


    July 2017
  25. SWANSON C, Shea SA, Wolfe P, Cain SW, et al
    Bone Turnover Markers After Sleep Restriction and Circadian Disruption: A Mechanism for Sleep-Related Bone Loss in Humans.
    J Clin Endocrinol Metab. 2017 Jul 26. doi: 10.1210/jc.2017-01147.
    PubMed     Text format     Abstract available


  26. BALASURIYA CND, Evensen KAI, Mosti MP, Brubakk AM, et al
    Peak Bone Mass and Bone Microarchitecture in Adults Born With Low Birth Weight Preterm or at Term: A Cohort Study.
    J Clin Endocrinol Metab. 2017;102:2491-2500.
    PubMed     Text format     Abstract available


    June 2017
  27. PASCHOU S, Dede AD, Anagnostis PG, Vryonidou A, et al
    Type 2 diabetes and osteoporosis: a guide to optimal management.
    J Clin Endocrinol Metab. 2017 Jun 21. doi: 10.1210/jc.2017-00042.
    PubMed     Text format     Abstract available


  28. LAMY O, Gonzalez-Rodriguez E, Aubry-Rozier B
    Response to Letter: Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation.
    J Clin Endocrinol Metab. 2017;102:2112.
    PubMed     Text format    


  29. RAO SD, Qiu S, Dhaliwal R, Bhadada SK, et al
    Letter to the Editor: Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation.
    J Clin Endocrinol Metab. 2017;102:2111.
    PubMed     Text format    


    May 2017
  30. VERROKEN C, Pieters W, Beddeleem L, Goemaere S, et al
    CORTICAL BONE SIZE DEFICIT IN ADULT PATIENTS WITH TYPE 1 DIABETES MELLITUS.
    J Clin Endocrinol Metab. 2017 May 22. doi: 10.1210/jc.2017-00620.
    PubMed     Text format     Abstract available


  31. SCHORR M, Marengi DA, Pulumo R, Yu E, et al
    Oxytocin and its relationship to body composition, bone mineral density and hip geometry across the weight spectrum
    J Clin Endocrinol Metab. 2017 May 10. doi: 10.1210/jc.2016-3963.
    PubMed     Text format     Abstract available


  32. OHLSSON C, Sundh D, Wallerek A, Nilsson M, et al
    Response to Letter: "Cortical Bone Area Predicts Incident Fractures Independently of Areal Bone Mineral Density in Older Men".
    J Clin Endocrinol Metab. 2017;102:1782.
    PubMed     Text format    


  33. ZHANG Y, Xiao H, Sheng ZF
    Letter to the Editor: "Cortical Bone Area Predicts Incident Fractures Independently of Areal Bone Mineral Density in Older Men".
    J Clin Endocrinol Metab. 2017;102:1780-1781.
    PubMed     Text format    


    April 2017
  34. GONZALEZ RODRIGUEZ E, Lamy O, Stoll D, Metzger M, et al
    High evening cortisol level is associated with low TBS and increased prevalent vertebral fractures. OsteoLaus study.
    J Clin Endocrinol Metab. 2017 Apr 4. doi: 10.1210/jc.2016-3804.
    PubMed     Text format     Abstract available


  35. WESSELING-PERRY K, Makitie RE, Valimaki VV, Laine T, et al
    Osteocyte protein expression is altered in low-turnover osteoporosis caused by mutations in WNT1 and PLS3.
    J Clin Endocrinol Metab. 2017 Apr 3. doi: 10.1210/jc.2017-00099.
    PubMed     Text format     Abstract available


    March 2017
  36. CHEMAITILLY W, Li Z, Krasin MJ, Brooke RJ, et al
    Premature Ovarian Insufficiency in Childhood Cancer Survivors: A Report from the St. Jude Lifetime Cohort.
    J Clin Endocrinol Metab. 2017 Mar 24. doi: 10.1210/jc.2016-3723.
    PubMed     Text format     Abstract available


  37. VALDERRABANO RJ, Lee J, Lui LY, Hoffman AR, et al
    Older Men with Anemia Have Increased Fracture Risk Independent of Bone Mineral Density.
    J Clin Endocrinol Metab. 2017 Mar 20. doi: 10.1210/jc.2017-00266.
    PubMed     Text format     Abstract available


  38. WANG Y, Wactawski-Wende J, Sucheston-Campbell LE, Preus L, et al
    Gene-hormone therapy interaction and fracture risk in postmenopausal women.
    J Clin Endocrinol Metab. 2017 Mar 6. doi: 10.1210/jc.2016-2936.
    PubMed     Text format     Abstract available


  39. BURR DB, Lane JE, Howe TS, Ng AC, et al
    Response to PD Miller, Underdiagnosis and Undertreatment of Osteoporosis: The Battle To Be Won.
    J Clin Endocrinol Metab. 2017;102:1088-1089.
    PubMed     Text format    


  40. TROVAS G
    Letter to the Editor: Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Nine Clinical Cases Report.
    J Clin Endocrinol Metab. 2017;102:1086.
    PubMed     Text format    


    February 2017
  41. NOTSU M, Yamauchi M, Yamamoto M, Nawata K, et al
    Primary aldosteronism as a risk factor for vertebral fracture.
    J Clin Endocrinol Metab. 2017 Feb 9. doi: 10.1210/jc.2016-3206.
    PubMed     Text format    


    January 2017
  42. VUORIMIES I, Mayranpaa MK, Valta H, Kroger H, et al
    Bisphosphonate Treatment and the Characteristics of Femoral Fractures in Children with Osteogenesis Imperfecta.
    J Clin Endocrinol Metab. 2017 Jan 17. doi: 10.1210/jc.2016-3745.
    PubMed     Text format     Abstract available


  43. WATTS NB, Cauley JA, Jackson RD, LaCroix AZ, et al
    No Increase in Fractures After Stopping Hormone Therapy: Results From the Women's Health Initiative.
    J Clin Endocrinol Metab. 2017;102:302-308.
    PubMed     Text format     Abstract available


    November 2016
  44. OHLSSON C, Sundh D, Wallerek A, Nilsson M, et al
    Cortical bone area predicts incident fractures independently of areal bone mineral density in older men.
    J Clin Endocrinol Metab. 2016 Nov 22:jc20163177.
    PubMed     Text format     Abstract available


  45. PAPADAKIS G, Hans D, Gonzalez-Rodriguez E, Vollenweider P, et al
    The Benefit of Menopausal Hormone Therapy on Bone Density and Microarchitecture Persists After its Withdrawal.
    J Clin Endocrinol Metab. 2016 Nov 17:jc20162695.
    PubMed     Text format     Abstract available


  46. CHAWLA H, Saha S, Kandaswamy D, Sharma R, et al
    Vertebral fractures and bone mineral density in patients with idiopathic hypoparathyroidism on long term follow-up.
    J Clin Endocrinol Metab. 2016 Nov 4:jc20163292.
    PubMed     Text format     Abstract available


    October 2016
  47. VALIMAKI VV, Makitie O, Pereira R, Laine C, et al
    Teriparatide Treatment in Patients with WNT1 or PLS3 Mutation-Related Early-Onset Osteoporosis - A Pilot Study.
    J Clin Endocrinol Metab. 2016 Oct 12:jc20162423.
    PubMed     Text format     Abstract available


  48. LAMY O, Gonzalez-Rodriguez E, Stoll D, Hans D, et al
    Severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical cases report.
    J Clin Endocrinol Metab. 2016 Oct 12:jc20163170.
    PubMed     Text format     Abstract available


    September 2016
  49. ESCHE J, Johner S, Shi L, Schonau E, et al
    Urinary citrate, an index of acid-base status, predicts bone strength in youths and fracture risk in adult females.
    J Clin Endocrinol Metab. 2016 Sep 27:jc20162677.
    PubMed     Text format     Abstract available


  50. MAJUMDAR SR, Leslie WD, Lix LM, Morin SN, et al
    Longer Duration of Diabetes Strongly Impacts Fracture Risk Assessment: The Manitoba BMD Cohort.
    J Clin Endocrinol Metab. 2016 Sep 7:jc20162569.
    PubMed     Text format     Abstract available


  51. MILLER PD, Pannacciulli N, Wagman RB, Cummings SR, et al
    Response to the Letter: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid.
    J Clin Endocrinol Metab. 2016;101:L91-2.
    PubMed     Text format    


  52. MAKRAS P, Polyzos SA, Anastasilakis AD
    Letter to the Editor: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid.
    J Clin Endocrinol Metab. 2016;101:L89-90.
    PubMed     Text format    


    August 2016
  53. KOCIJAN R, Muschitz C, Geiger E, Skalicky S, et al
    Circulating microRNA signatures in patients with idiopathic and postmenopausal osteoporosis and fragility fractures.
    J Clin Endocrinol Metab. 2016 Aug 23:jc20162365.
    PubMed     Text format     Abstract available


  54. WAGENKNECHT LE, Divers J, Register TC, Russell GB, et al
    Bone mineral density and progression of subclinical atherosclerosis in African Americans with type 2 diabetes.
    J Clin Endocrinol Metab. 2016 Aug 23:jc20161934.
    PubMed     Text format     Abstract available


  55. SUGIYAMA T, Oda H
    Letter to the Editor: Combination Treatment With Teriparatide and Denosumab in Osteoporosis.
    J Clin Endocrinol Metab. 2016;101:L80-1.
    PubMed     Text format    


    June 2016
  56. CARTWRIGHT B, Robinson J, Seed PT, Fogelman I, et al
    Hormone replacement therapy versus the combined oral contraceptive pill in premature ovarian failure: a randomised controlled trial of the effects on bone mineral density.
    J Clin Endocrinol Metab. 2016 Jun 24:jc20154063.
    PubMed     Text format     Abstract available


  57. CHANG PY, Gold EB, Cauley JA, Johnson WO, et al
    Triglyceride Levels and Fracture Risk in Midlife Women: Study of Women's Health Across the Nation (SWAN).
    J Clin Endocrinol Metab. 2016 Jun 13:jc20161366.
    PubMed     Text format     Abstract available


  58. MILLER PD, Pannacciulli N, Brown JP, Czerwinski E, et al
    Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates.
    J Clin Endocrinol Metab. 2016 Jun 6:jc20161801.
    PubMed     Text format     Abstract available


    May 2016
  59. SHANBHOGUE VV, Finkelstein JS, Bouxsein ML, Yu EW, et al
    Association between insulin resistance and bone structure in non-diabetic postmenopausal women.
    J Clin Endocrinol Metab. 2016 May 31:jc20161726.
    PubMed     Text format     Abstract available


  60. AFSHINNIA F, Pennathur S
    Association of Hypoalbuminemia with Osteoporosis: Analysis of the National Health and Nutrition Examination Survey.
    J Clin Endocrinol Metab. 2016 May 4:jc20161099.
    PubMed     Text format     Abstract available


  61. MORELLI V, Eller-Vainicher C, Palmieri S, Cairoli E, et al
    Prediction of vertebral fractures in patients with monolateral adrenal incidentalomas.
    J Clin Endocrinol Metab. 2016 May 4:jc20161423.
    PubMed     Text format     Abstract available


  62. SUGIYAMA T, Kim YT, Oda H
    Letter to the Editor: Strontium Ranelate in the Treatment of Osteoporosis: A Possible Mechanism.
    J Clin Endocrinol Metab. 2016;101:L64-5.
    PubMed     Text format    


  63. AMREIN K, Perl S, Dimai HP
    Letter to the Editor: Preadmission Bisphosphonate and Mortality in Critically Ill Patients.
    J Clin Endocrinol Metab. 2016;101:L60-1.
    PubMed     Text format    


    March 2016
  64. MAJUMDAR SR, Josse RG, Lin M, Eurich DT, et al
    Does Sitagliptin Affect the Rate of Osteoporotic Fractures in Type-2 Diabetes? Population-Based Cohort Study.
    J Clin Endocrinol Metab. 2016 Mar 1:jc20154180.
    PubMed     Text format     Abstract available


  65. MILLER PD
    Underdiagnoses and Undertreatment of Osteoporosis: The Battle to Be Won.
    J Clin Endocrinol Metab. 2016;101:852-859.
    PubMed     Text format     Abstract available


  66. KRONENBERG HM
    Bone and Mineral Metabolism: Where Are We, Where Are We Going, and How Will We Get There?
    J Clin Endocrinol Metab. 2016;101:795-8.
    PubMed     Text format     Abstract available


    February 2016
  67. UPALA S, Sanguankeo A
    Association Between Hyponatremia, Osteoporosis and Fracture: a Systematic Review and Meta-analysis.
    J Clin Endocrinol Metab. 2016 Feb 25:jc20154228.
    PubMed     Text format     Abstract available


  68. CARBONE L, Johnson KC, Huang Y, Pettinger M, et al
    Sodium Intake and Osteoporosis. Findings from the Women's Health Initiative.
    J Clin Endocrinol Metab. 2016 Feb 10:jc20154017.
    PubMed     Text format     Abstract available


  69. DEMPSTER DW, Zhou H, Recker RR, Brown JP, et al
    Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study.
    J Clin Endocrinol Metab. 2016 Feb 9:jc20154181.
    PubMed     Text format     Abstract available


    January 2016
  70. LEE P, Ng C, Slattery A, Nair P, et al
    Preadmission bisphosphonate and mortality in critically ill patients.
    J Clin Endocrinol Metab. 2016 Jan 18:jc20153467.
    PubMed     Text format     Abstract available


  71. LEE SH, Cho EH, Ahn SH, Kim HM, et al
    Prediction of Future Osteoporotic Fracture Occurrence by Genetic Profiling: A 6-year Follow-up Observational Study.
    J Clin Endocrinol Metab. 2016 Jan 12:jc20153972.
    PubMed     Text format     Abstract available


  72. TABATABAI LS, Bloom J, Stewart S, Sellmeyer DE, et al
    FSH Levels Predict Bone Loss in Premenopausal Women Treated for Breast Cancer More Than One Year After Treatment.
    J Clin Endocrinol Metab. 2016 Jan 12:jc20153149.
    PubMed     Text format     Abstract available


  73. MARTIN BR, McCabe GP, McCabe L, Jackson GS, et al
    Effect of Hesperidin with and without a Calcium (Calcilock(R)) Supplement on Bone Health in Postmenopausal Women.
    J Clin Endocrinol Metab. 2016 Jan 11:jc20153767.
    PubMed     Text format     Abstract available


  74. WALKER MD, Nishiyama KK, Zhou B, Cong E, et al
    Effect of Low Vitamin D on Volumetric Bone Mineral Density, Bone Microarchitecture and Stiffness in Primary Hyperparathyroidism.
    J Clin Endocrinol Metab. 2016 Jan 8:jc20154218.
    PubMed     Text format     Abstract available


    December 2015
  75. MUKA T, de Jonge EA, Kiefte-de Jong JC, Uitterlinden AG, et al
    The influence of serum uric acid on bone mineral density, hip geometry and fracture risk: The Rotterdam Study.
    J Clin Endocrinol Metab. 2015 Dec 18:jc20152446.
    PubMed     Text format     Abstract available


  76. KIZILGUL M, Sencar E, Ucan B, Ozbek M, et al
    Letter to the Editor: Possible Decrease in GIP Levels May Explain Increased Plasma Dipeptidyl Peptidase-4 Activity-Associated Osteoporosis.
    J Clin Endocrinol Metab. 2015;100:L128-9.
    PubMed     Text format    


    November 2015
  77. AFSHINNIA F, Wong KK, Sundaram B, Ackermann RJ, et al
    Hypoalbuminemia and Osteoporosis: Reappraisal of a Controversy.
    J Clin Endocrinol Metab. 2015 Nov 24:jc20153212.
    PubMed     Text format     Abstract available


  78. WATTS NB, Bilezikian JP, Usiskin K, Edwards R, et al
    Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.
    J Clin Endocrinol Metab. 2015 Nov 18:jc20153167.
    PubMed     Text format     Abstract available


  79. BILEZIKIAN JP, Watts NB, Usiskin K, Polidori D, et al
    Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin.
    J Clin Endocrinol Metab. 2015 Nov 18:jc20151860.
    PubMed     Text format     Abstract available


  80. SALVATORI R
    Letter to the Editor: Comment on "Effect of Growth Hormone Treatment on Fractures and Quality of Life in Postmenopausal Osteoporosis: A 10-Year Follow-Up Study" by Kratz E., et al.
    J Clin Endocrinol Metab. 2015;100:L107.
    PubMed     Text format    


  81. KRANTZ E, Trimpou P, Landin-Wilhelmsen K
    Response to the Letter by Salvatori R.
    J Clin Endocrinol Metab. 2015;100:L108.
    PubMed     Text format    


  82. VAN VARSSEVELD NC, Sohl E, Drent ML, Lips P, et al
    Gender-Specific Associations of Serum Insulin-Like Growth Factor-1 With Bone Health and Fractures in Older Persons.
    J Clin Endocrinol Metab. 2015;100:4272-81.
    PubMed     Text format     Abstract available


  83. GEORGE S, Weber DR, Kaplan P, Hummel K, et al
    Short-Term Safety of Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience.
    J Clin Endocrinol Metab. 2015;100:4163-71.
    PubMed     Text format     Abstract available


    October 2015
  84. CHAVASSIEUX P, Portero-Muzy N, Paul Roux J, Garnero P, et al
    Are Biochemical Markers of Bone Turnover Representative of Bone Histomorphometry in 370 Postmenopausal Women?
    J Clin Endocrinol Metab. 2015 Oct 27:jc20152957.
    PubMed     Text format     Abstract available


  85. KIZILGUL M, Ozcelik O, Apaydin M, Ozbek M, et al
    Letter to the Editor: Possible Mechanisms of Hyponatremia-Induced Osteoporosis.
    J Clin Endocrinol Metab. 2015;100:L89-90.
    PubMed     Text format    


  86. CONTE C, Cecere A, Guglielmi G, Napoli N, et al
    Letter to the Editor: "GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women" by Iepsen E.W., et al.
    J Clin Endocrinol Metab. 2015;100:L92-3.
    PubMed     Text format    


  87. VERBALIS J
    Response to the Letter to the Editor.
    J Clin Endocrinol Metab. 2015;100:L91.
    PubMed     Text format    


  88. PACCOU J, Hardouin P, Cotten A, Penel G, et al
    The Role of Bone Marrow Fat in Skeletal Health: Usefulness and Perspectives for Clinicians.
    J Clin Endocrinol Metab. 2015;100:3613-21.
    PubMed     Text format     Abstract available


    September 2015
  89. CRANDALL CJ, Hovey KM, Andrews CA, Cauley JA, et al
    Bone Mineral Density as a Predictor of Subsequent Wrist Fractures: Findings from the Women's Health Initiative Study.
    J Clin Endocrinol Metab. 2015 Sep 14:jc20152568.
    PubMed     Text format     Abstract available


  90. COHEN A, Kamanda-Kosseh M, Recker RR, Lappe JM, et al
    Bone Density after Teriparatide Discontinuation in Premenopausal Idiopathic Osteoporosis.
    J Clin Endocrinol Metab. 2015 Sep 10:jc20152829.
    PubMed     Text format     Abstract available


    August 2015
  91. TAN LJ, Wang ZE, Wu KH, Chen XD, et al
    Bivariate Genome-Wide Association Study Implicates ATP6V1G1 as a Novel Pleiotropic Locus Underlying Osteoporosis and Age at Menarche.
    J Clin Endocrinol Metab. 2015 Aug 27:jc20152095.
    PubMed     Text format     Abstract available


  92. KRANTZ E, Trimpou P, Landin-Wilhelmsen K
    Effect of Growth Hormone Treatment on Fractures and Quality of Life in Postmenopausal Osteoporosis: A 10-Year Follow-Up Study.
    J Clin Endocrinol Metab. 2015 Aug 27:jc20151757.
    PubMed     Text format     Abstract available


  93. ZHENG T, Yang L, Liu Y, Liu H, et al
    Increased plasma dipeptidyl peptidase-4 activities are associated with high prevalence of osteoporosis in postmenopausal women with normal glucose tolerance.
    J Clin Endocrinol Metab. 2015 Aug 10:jc20152233.
    PubMed     Text format     Abstract available


  94. BREITLING LP
    Liver enzymes and bone mineral density in the general population.
    J Clin Endocrinol Metab. 2015 Aug 4:jc20152016.
    PubMed     Text format     Abstract available


    July 2015
  95. CUMMINGS EA, Ma J, Fernandez CV, Halton J, et al
    Incident Vertebral Fractures in Children with Leukemia During the Four Years Following Diagnosis.
    J Clin Endocrinol Metab. 2015 Jul 14:JC20152176.
    PubMed     Text format     Abstract available


  96. ING SW, Orchard TS, Lu B, LaMonte MJ, et al
    TNF Receptors Predict Incident Hip Fracture Risk in the WHI Study and Fatty Acid Intake Does Not Modify this Association.
    J Clin Endocrinol Metab. 2015 Jul 10:JC20151662.
    PubMed     Text format     Abstract available


  97. TSAI JN, Zhu Y, Foley K, Lee H, et al
    Comparative Resistance to Teriparatide-Induced Bone Resorption With Denosumab or Alendronate.
    J Clin Endocrinol Metab. 2015;100:2718-23.
    PubMed     Text format     Abstract available


    June 2015
  98. MIRIAM RACHEL USALA G, Fernandez SJ, Mete M, Cowen L, et al
    Hyponatremia is Associated with Increased Osteoporosis and Bone Fractures in a Large U. S. Health System Population.
    J Clin Endocrinol Metab. 2015 Jun 17:jc20151261.
    PubMed     Text format     Abstract available


  99. IEPSEN EW, Lundgren JR, Hartmann B, Pedersen O, et al
    GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women.
    J Clin Endocrinol Metab. 2015 Jun 4:jc20151176.
    PubMed     Text format     Abstract available


    May 2015
  100. COSMAN F, Nieves JW, Zion M, Garrett P, et al
    Daily or Cyclical Teriparatide Treatment in Women with Osteoporosis on no Prior Therapy and Women on Alendronate.
    J Clin Endocrinol Metab. 2015 May 11:jc20151715.
    PubMed     Text format     Abstract available


  101. CHEN CL, Chen NC, Liang HL, Hsu CY, et al
    Effects of Denosumab and Calcitriol on Severe Secondary Hyperparathyroidism in Dialysis Patients with Low Bone Mass.
    J Clin Endocrinol Metab. 2015 May 8:jc20151259.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Osteoporosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: